Proteins and Peptides

25 Feb 2021 I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency
23 Feb 2021 NeoImmuneTech Receives U.S. FDA IND Clearance for Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy
23 Feb 2021 Revance Announces Positive Topline Phase 2 Data Supporting Advancement of DaxibotulinumtoxinA for Injection for the Treatment of Upper Limb Spasticity
17 Feb 2021 Nektar Announces Agreement for Phase 2/3 Study of IL-2 Pathway Agonist, Bempegaldesleukin, in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN)
17 Feb 2021 Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
16 Feb 2021 Sesen Bio Announces FDA Acceptance and Priority Review of its Biologics License Application for Vicineum™
16 Feb 2021 ReAlta Life Sciences Doses First Subject in Phase 1 Healthy Volunteers Study of RLS-0071
15 Feb 2021 Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart
12 Feb 2021 Xeris Pharmaceuticals Receives European Commission Approval of Ogluo™ (glucagon) Injection for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Years and Over With Diabetes Mellitus
12 Feb 2021 Amicus’ AT-GAA Shows Clinically Meaningful & Significant Improvements in Both Musculoskeletal and Respiratory Measures in Late-Onset Pompe Disease Compared to Standard of Care in Pivotal Phase 3 PROPEL Study
10 Feb 2021 Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021
10 Feb 2021 BOTOX® (onabotulinumtoxinA) Receives FDA Approval for Pediatric Detrusor Overactivity Associated with a Neurologic Condition
10 Feb 2021 Affibody and Inmagene announce IND Clearance for Izokibep (ABY-035) for the treatment of Ankylosing Spondylitis
09 Feb 2021 Brooklyn ImmunoTherapeutics Announces Phase 2 Trial of IRX-2 in Combination with Pembrolizumab and Chemotherapy in Triple Negative Breast Cancer
08 Feb 2021 Entera Bio Initiates New Research Program For Oral GLP-2
08 Feb 2021 Onco-immunology Company Pan Cancer T Launched as Spin-off from Erasmus Medical Center
04 Feb 2021 Molecular Partners and Novartis COVID-19 Antiviral Candidate, Ensovibep, Maintains Binding and Neutralization of New Viral Variants in vitro
04 Feb 2021 Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
03 Feb 2021 VectivBio Announces First Patient Dosed in Pivotal Phase 3 Trial of Apraglutide for the Treatment of Short Bowel Syndrome
03 Feb 2021 4D pharma presents update on oncology program
01 Feb 2021 Biogen Announces FDA Approval of PLEGRIDY® (peginterferon beta-1a) Intramuscular Administration for Multiple Sclerosis
01 Feb 2021 Positive Early Study Results Help Pave Wave for Titan Pharmaceuticals to Move Forward with its JT-09 ProNeura® Development Program
01 Feb 2021 Gemini Therapeutics Announces Initiation of GEM103 Phase 2a Study as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMD Patients at Risk for Progressive Vision Loss Due to Macular Atrophy
01 Feb 2021 Ovoca Bio Announces First Patient Enrolled in Phase II Dose Ranging Study Assessing BP-101 for HSDD
29 Jan 2021 Novo Nordisk receives positive opinion from the European regulatory authorities for once-weekly Sogroya® (somapacitan) for the treatment of adult growth hormone deficiency

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up